See The Bigger Picture
In IO Clinical Trials

Get an exclusive first look at the results of our

‘What Pharma Wants’
Survey

Challenge • Create • Transform
We interviewed 15 Pharmaceutical and Biotech Companies to understand challenges in IO clinical trials and how they would use 89Zr cefmirlimab berdoxam (CD8 ImmunoPET)

Here is what we found:

- Identified the Top 6 current challenges in IO trials
- Perceived best time to use CD8 ImmunoPET in clinical trials
- How they will use CD8 ImmunoPET in clinical development
- Importance of measuring CD8 in tumors
- The single most important, differentiated value of CD8 ImmunoPET

This is an investigational product that has not yet been approved by the FDA
“It's a really good tool to see the biodistribution in the entire body. Not only in your area of interest ... So overall I think this is a wonderful tool. And it's really nice to see in the initial scan how the CD8 cells are sequestered in the periphery ... that they are trapped in the periphery and somehow cannot penetrate. This is one of the biggest problems in solid cancers, that the response is quite often in the periphery. But then the most dangerous area that is the core, doesn't receive any...So it's very encouraging to see the entire tumor lighting up after treatment with your tool. And that we can diagnose it or image it...I really like this tool.”

– Large Pharma 1

“Earlier time to result? That's part of it. Because in clinical trial we don't have time to wait for data. If the data arrives too late for decision-making, then it's just a waste. And the advantage of images is that you do a scan, and you see. You don't need to wait a lot, you have your image or when it already knows the results, more or less. So that's an advantage.”

– Large Pharma 2

“...absolutely perfect. I believe we definitely need such a tool widely used in the hospital.”

– Large Pharma 3

“...If you can prove that this is the most sensitive and reliable way to show productive immune responses...showing an equivalent or likely better outcome than FDG-PET or other biopsy techniques would really add value. If it's statistically more likely to predict your response I think that makes people get really excited about it.”

– Large Pharma 4

“The images looked really, really nice ... this is a valuable technique, because you can follow multiple nodes in a patient and track those, which you can't do obviously with biopsies...Guide biopsy collection ... is an advantage too...Quick assessment of MOA ... along those lines there is an important thing ... we can design our clinical studies where we have our backbone treatment, our checkpoint inhibitor...but we want to evaluate combinations quickly. This would be a way for us to judge quickly if a treatment in a particular cancer can bring T cells into the tumor and then quickly screen drugs in our pipeline.”

– Large Pharma 5

This is an investigational product that has not yet been approved by the FDA.
Schedule a conversation to learn more

Gregory Frank, PhD – USA, West Coast
gfrank@imaginab.com

Matthew Ennis – USA, Central & East Coast
mennis@imaginab.com

Mandeep Sehmi, PhD – Rest of the World
msehmi@imaginab.com